Anti-inflammatory efficacy
Evaluate candidate activity in an IMQ-induced inflammatory skin-disease setting.
IMMUNOLOGY & INFLAMMATION MODEL
IMQ-Induced Psoriasis Models
The documented dermatology platform includes imiquimod-induced psoriasis models in both mice and rats for inflammatory skin-disease pharmacology.
Species, strain, IMQ regimen, treatment schedule, skin assessment, tissue collection, and biomarker plan are confirmed for each program.
MODEL OVERVIEW
Rodent IMQ models for inflammatory skin-disease studies.
IMQ-induced psoriasis studies can be run in mouse or rat platforms and scoped around the candidate mechanism, dosing route, study duration, and required skin, tissue, biomarker, or exposure outputs.
Therapeutic areaPsoriasis, Dermatology
SpeciesMouse, Rat
Model formatIMQ-induced psoriasis
Typical useEfficacy, Tissue, Biomarkers
TYPICAL APPLICATIONS
What this model can support.
Route & formulation studies
Align topical or systemic treatment designs with the intended product profile when technically appropriate.
Skin tissue analysis
Protocol-defined skin collection for histology, molecular, or other downstream analysis.
PK/PD & biomarkers
Integrate exposure, pharmacodynamic, and inflammatory biomarker measurements when required.
COMMON READOUTS
Readouts selected around the study question.
Endpoints are finalized with the selected model, species or strain, treatment design, and partner laboratory before study placement.
Skin phenotype
Protocol-defined skin-disease and treatment-response assessments.
Histopathology
Skin tissue collection and histology when included in the protocol.
Biomarkers
Inflammatory or mechanism-linked biomarkers selected for the program.
Exposure
Systemic or selected tissue exposure when PK/PD work is incorporated.
The source documentation confirms IMQ-induced mouse and rat psoriasis models but does not disclose a single standardized strain or induction regimen.
STUDY DESIGN
Key factors aligned before execution.
- Mouse or rat study platform
- Strain and IMQ regimen
- Topical or systemic dosing strategy
- Treatment timing and study duration
- Skin assessment and histology plan
- PK/PD and biomarker requirements
Discuss Your Program
Share the compound, mechanism, development question, preferred model, and intended endpoints. We can review fit, feasibility, and the appropriate partner-laboratory route for a IMQ Psoriasis study.Required fields are marked with an asterisk(*).